The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Managing the Neuropsychiatric Symptoms of Dementia (NPSD)
Date
March 24, 2017
Credits
1.5 CH | 1.5 Rx | Expired March 25, 2019
$3500
Standard Price
Members save $5
This session describes the common neuropsychiatric symptoms of dementia and the factors that may lead to problematic behaviors, as well as defines the appropriate pharmacological roles for cholinesterase inhibitors, NMDA antagonist, antipsychotics, antidepressants, anxiolytic medications, and anti-seizure medications in managing NPSD. Drugs that may not have proven effective or may increase NPSD in clinical practice are identified.
Contact hours available until 3/25/19.
Requirements for Successful Completion: Complete the learning activity in its entirety and complete the online CNE evaluation. You will be able to print your CNE certificate at any time after you complete the evaluation.
Faculty, Planners and Authors Conflict of Interest Disclosure:
Planning Committee: No planning committee member discloses a potential or actual conflict of interest.
Speakers: There are no disclosures to declare.
Commercial Support and Sponsorship: No commercial support or corporate sponsorship was received.
Accreditation Statement: This educational activity is jointly provided by Anthony J. Jannetti, Inc. (AJJ) and GAPNA.
Anthony J. Jannetti, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Learning Outcome: After completing this learning activity, the learner will be able to summarize prescribing considerations for managing the neuropsychiatric symptoms of dementia.
The effects of aging on bowel function in older adults, as well as pharmacodynamics and kinetics of common and not-so-common drugs to mitigate constipation issues are addressed…
This session provides a pain management overview with a focus on opioids, adjuvant therapies, and alternative therapies, and discusses barriers to care…
Learn about the endocannabinoid system, endogenous cannabinoids, and exogenous cannabinoids as they relate to patient care. This session also provides guidance regarding safe products and practices for adult and elderly patients…
50% of HIV-positive adults in the US are age 50 or older and hepatitis C is now a curable ill- ness due to treatment advances. This session emphasizes basics of antiretroviral therapy and new hepatitis C treatments…
Privacy Policy Update: We value your privacy and want you to understand how your information is being used. To make sure you have current and accurate information about this sites privacy practices please visit the privacy center by clicking here.